PacBio's Q3: Challenges & Opportunities
Update: 2025-11-12
Description
PacBios Q3 earnings report, released on November 12th, showed a revenue shortfall of 4.5% due to fewer instrument shipments and lower selling prices. Despite this, consumable sales hit an all-time high, indicating increased usage of existing machines. The company plans to focus on commercializing new chemistry and multi-use SMRT Cells, expanding into clinical and population genomics, and hoping for improved funding in the US.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
